HighVista Strategies LLC

Position in ELVN — Enliven Therapeutics, Inc.

CIK 1335325 BOSTON, MA

Position in ELVN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$6,996,699

+$4,131,101 QoQ

Shares Held

137,866

+88.6% QoQ

Ownership

0.188%

of shares outstanding

% of Portfolio

1.60%

of 13F equity value

Holder Rank

#68

of 210 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

HighVista Strategies LLC holds $278,365,756 across 70 Biotechnology names. ELVN ranks #11 (2.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ABVX	Abivax S.A.	113,031	$15,062,511
2	RVMD	Revolution Medicines, Inc.	66,983	$12,544,576
3	DFTX	Definium Therapeutics, Inc.	242,884	$11,425,263
4	IMVT	Immunovant, Inc.	277,873	$10,706,446
5	PRAX	Praxis Precision Medicines, Inc.	30,210	$10,114,005
6	RLAY	Relay Therapeutics, Inc.	506,235	$9,471,656
7	PCVX	Vaxcyte, Inc.	149,739	$8,704,328
8	TNGX	Tango Therapeutics, Inc.	260,070	$8,129,788

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$6,996,699	137,866	+88.6%	Shares	Sole	2026-08-14
2026-03-31	$2,865,598	73,102	-11.4%	Shares	Sole	2026-05-15
2025-12-31	$1,271,054	82,536	-68.1%	Shares	Sole	2026-02-17
2025-09-30	$5,304,493	259,135	+83.1%	Shares	Sole	2025-11-14
2025-06-30	$2,838,810	141,516	+25.8%	Shares	Sole	2025-08-14
2025-03-31	$2,213,193	112,459	0.0%	Shares	Sole	2025-05-15
2024-12-31	$2,530,327	112,459	0.0%	Shares	Sole	2025-02-14
2024-09-30	$2,872,202	112,459	-6.1%	Shares	Sole	2024-11-14
2024-06-30	$2,799,468	119,789	-5.6%	Shares	Sole	2024-08-14
2024-03-31	$2,231,361	126,854	-7.6%	Shares	Sole	2024-05-15
2023-12-31	$1,899,415	137,241	+10.2%	Shares	Sole	2024-02-14
2023-09-30	$1,701,858	124,587	+2.9%	Shares	Sole	2023-11-14
2023-06-30	$2,471,099	121,073	—	Shares	Sole	2023-08-14
No filing history on record for this holder in this stock.